Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides

• Published in: Nature (London) Vol. 307; no. 5953; p. 755
• Main Authors: Fuhrmann, U, Bause, E, Legler, G, Ploegh, H
• Format: Journal Article
• Language: English
• Published: England 23.02.1984
• Subjects: 1-Deoxynojirimycin; Alkaloids - pharmacology; Animals; Cytoplasm - metabolism; Glucosamine - analogs & derivatives; Glucosamine - pharmacology; Glycoproteins - metabolism; Glycoside Hydrolases; Hybridomas; Immunoglobulin D - metabolism; Immunoglobulin M - metabolism; Mannosidases - antagonists & inhibitors; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Mice; Oligosaccharides - metabolism; Protein Processing, Post-Translational; Swainsonine
• ISSN: 0028-0836; 1476-4687
• DOI: 10.1038/307755a0

Many secretory and membrane proteins are glycoproteins carrying asparagine-linked (N-linked) oligosaccharides. There are two types of N-linked glycans, referred to as high-mannose and complex type, respectively. Biosynthesis of N-linked glycans of the complex type proceeds via a high-mannose intermediate. After the initial transfer of a high-mannose oligosaccharide with the composition (Glc)3(Man)9(GlcNAc)2 from a lipid carrier to the nascent polypeptide chain, trimming reactions take place. Trimming glucosidases remove the glucose residues quantitatively and mannosidases IA/B and II can remove all but three mannose residues. After trimming, terminal sugars such as N-acetylglucosamine, galactose, sialic acid and fucose may be added and result in the conversion to a glycan of the complex type. Because suitable inhibitors were lacking, it was difficult to assess the importance of the trimming reactions for proper intracellular traffic, modification reactions other than the addition of terminal sugars, or as regulatory steps in glycoprotein processing. Here we describe the action of 1-deoxymannojirimycin (1,5-dideoxy-1,5-imino-D-mannitol, dMM; Fig. 1) on the biosynthesis of IgM and IgD. dMM is the mannose analogue of 1-deoxynojirimycin (dNM; Fig. 1), itself a glucosidase inhibitor. We present evidence that dMM is a mannosidase inhibitor. In vivo dMM inhibits the equivalent of the mannosidase IA/B activities and blocks conversion of high-mannose to complex oligosaccharides. It is the first such inhibitor to be reported. Interference with the biosynthetic pathway of N-linked glycans could prove to be a powerful way to manipulate carbohydrate structure in vivo.